Employing rational novel agent combination therapy to improve transplant cure rates for relapsed/refractory Hodgkin Lymphoma

From Wikispore
Jump to navigation Jump to search
Description: Hodgkin Lymphoma (HL) is a rare malignancy, with 500 new cases annually in young Australians. While 70 per cent of patients are cured with front line treatment, 30 per cent of patients require second line therapy which often fails resulting in death. Immunotherapy and targeted therapies have dramatically improved survival in haematological malignancies. This study will combine two agents currently approved in recurrent HL to maximise survival of these young Australians.
Dates

State ongoing
Start 2021-01-01
End 2026-01-01
Form updated 2023-11-15

Report authors
Portia Dilena (link)
Jack Nunn (link)
Checked STARDIT report data
Location
Australia
URL
template:str right/Ga/Show/9d10d108-a60a-443f-90b2-e834774a542b
Aims
maximise survival of young Australians with Hodgkin Lymphoma
Category
research

Inputs

individual

Eliza Hawkes


Task: Lead Chief Investigator
Compensation: paid
funding

(link)


1,225,487.40 (AUD)

Outputs and impacts

Retrieved from "https://wikispore.wmflabs.org/w/index.php?title=Employing_rational_novel_agent_combination_therapy_to_improve_transplant_cure_rates_for_relapsed/refractory_Hodgkin_Lymphoma&oldid=10016"